Roche Holding AG
SIX:ROG
Roche Holding AG
SIX:ROG
Price:
361
CHF
0.28%
Market Cap:
CHf292.1B
Relative Value
The Relative Value of one
ROG
stock under the Base Case scenario is
300.87
CHF.
Compared to the current market price of 361 CHF,
Roche Holding AG
is
Overvalued by 17%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ROG
Relative Value
Base Case
300.87
CHF
Overvaluation 17%
Multiples Across Competitors
ROG Competitors Multiples
Roche Holding AG Competitors
Roche Holding AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CH |
|
Roche Holding AG
SIX:ROG
|
287.6B CHF | 4.7 | 30.6 | 12.9 | 15.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
986.4B USD | 15.1 | 47.7 | 32.1 | 34.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.1B USD | 6.2 | 21.9 | 15.2 | 18.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
233.4B GBP | 5.4 | 31.2 | 17.2 | 24.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
241B CHF | 5.5 | 22.2 | 13.7 | 17.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
301.2B USD | 4.6 | 16.5 | 10.3 | 12.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 333.1 | 835.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK | 4.4 | 13.3 | 9.7 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
157.3B USD | 2.5 | 20.2 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.4B USD | 2.6 | 17.5 | 6.8 | 8.8 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
89B GBP | 2.7 | 15.6 | 7.8 | 11.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
